 |
|
|
|
|
|
|
|
|
|
| |
 |
322 - Update: A Phase I Study of NGF Ex Vivo Gene Therapy for Alzheimer�s Disease
|
|
|
| |
|
419 - Update: Intratumoral Injections of a Replication-Incompetent Adenoviral Vector Encoding a Factor VII Immunoconjugate to Induce a Cytolytic Immune Response Against Melanoma Tumors: A Pilot Trial
|
|
|
| |
|
469 - Update: Subthalamic GAD Gene Transfer in Parkinson's Disease Patients Who Are Candidates for Deep-Brain Stimulatio
|
|
|
| |
|
488 - Update: A Phase I, Open-Label Clinical Trial of the Safety and Tolerability of Single Escalating Doses of Autologous CD4 T Cells Transduced with VRX496 in HIV-Positive Subjects
|
|
|
| |
|
550: A Phase I/II Study of an Antitumor Vaccination Using (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Relapsed or Refractory Breast Cancer
|
|
|
| |
|
556: A Phase I, Open-Label, Dose-Escalation Trial Evaluating the Safety and Immunogenicity of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC)
|
|
|
| |
|
563: Administration of Peripheral Blood T Cells and Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes Transduced To Express GD-2-Specific Chimeric T-Cell Receptors to Patients With Neuroblastoma
|
|
|
| |
|
570: Use of in vivo Expression Technology To Identify Virulence Factors and Protective Antigens of Vibrio cholerae 01
|
|
|
| |
|
575: A Phase I Study of NT-501, An Implant of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotropic Factor (CNTF), in Patients with Retinitis Pigmentosa
|
|
|
| |
|
588: A Phase I Dose- Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector containing the TNFR: Fc Fusion Gene in Rheumatoid Arthritis
|
|
|
| |
|
589: A Phase 1 Study in Glaucoma Subjects Receiving SCH 412499 (rAd-p21) Administered as a Single Injection into the Subconjunctival Space Prior to Primary Trabeculectomy
|
|
|
| |
|
592: A Phase 1 Study to Determine the Safety and Immunogenicity of Vaccination With Listeria Monocytogenes Expressing Human Papillomavirus Type 16 E7 for the Treatment of Progressive, Recurrent, and Advanced Squamous Cell Cancer of the Cervix
|
|
|
| |
|
593: A Phase I Open-label Safety Study of Intrastriatal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-amino acid Decarboxylase (AAV-hAADC-2) in Subjects With Advanced Parkinson's Disease [AAV-hAADC-2-003]
|
|
|
| |
|
594: A Phase I Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using Tissue Gene-C in Patients with Degenerative Joint Disease of the Knee Prior to Total Knee Arthroplasty
|
|
|
| |
|
610: A Phase I/II Study of the Treatment of Recurrent or Progressive Malignant Glioma Using Autologous Bone Marrow-Derived Stromal Cells (BMSC) Nonvirally Transduced to Express IL-12
|
|
|
| |
|
613: Phase I Dose-Escalation Study of Intratumoral Herpes Simplex Virus-1 Mutant rRp450 in Patients with Refractory Sarcoma or Neuroblastoma
|
|
|
| |
|
614: First Time in Human Safety Study of Streptococcus mutans Lactic Acid-Deficient Effector Strain (A2JM) Administered in Conjunction with Twice-Daily Dose of D-Alanine Mouthwash in Healthy Adult Male Subjects for Replacement Therapy as an Aid in the Protection Against Dental Caries
|
|
|
| |
|
619 - Update: Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis
|
|
|
| |
|
622: Adenylyl Cyclase VI Gene Transfer for Congenital Heart Failure
|
|
|
| |
|
623: A Phase I/II, Dose-Escalating, Randomized and Controlled Study to Assess the Safety, Tolerability, and Efficacy of CERE-110 (Adeno-Associated Virus [AAV]-Based, Vector-Mediated Delivery of Beta-Nerve Growth Factor [NGF]) in Subjects with Mild to Moderate Alzheimer�s Disease
|
|
|
| |
|
623 - Update: A Phase I/II, Dose-Escalating, Randomized and Controlled Study to Assess the Safety, Tolerability, and Efficacy of CERE-110 (Adeno-Associated Virus [AAV]-Based, Vector-Mediated Delivery of Beta-Nerve Growth Factor [NGF]) in Subjects with Mild to Moderate Alzheimer�s Disease
|
|
|
| |
|
624: A Phase I Trial of Conditionally Replication-Competent Adenovirus (Delta-24-RGD) for Recurrent Malignant Gliomas
|
|
|
| |
|
625: A Phase I Study of a Tropism-Modified Conditionally Replicative Adenoviral Vector (Ad5-?24RGD) for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients
|
|
|
| |
|
629: A Phase I Dose-Escalation Trial of vvDD-CDSR (Double-Deleted Vaccinia Virus Plus CD/SMR) Administered by Intratumoral Injection in Patients with Superficial Injectable Tumors
|
|
|
| |
|
633: A Phase I Trial of Immunotherapy with BHT-3009 Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis
|
|
|
| |
|
638: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus 1-Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient Adults
|
|
|
| |
|
641: A Phase I, Open-Label, Nonrandomized, Dose-Escalation, Multicenter Therapeutic Trial of the Safety, Immunogenicity and Efficacy of GI-4000, an Inactivated Recombinant Saccharomyces cerevisiae Immunotherapeutic Expressing Three Different Mutations of the Ras Oncoprotein, in Patients with Solid Tumors Expressing Mutations in Ras
|
|
|
| |
|
642: A Phase I Trial of Gene Transfer during VAD Support with SERCA2a
|
|
|
| |
|
643: A Phase I/II Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder after Bacillus Calmette-Guerin Failure
|
|
|
| |
|
669: Hippocampal NPY Gene Transfer in Subjects with Intractable Mesial Temporal Lobe Epilepsy
|
|
|
| |
|
675: Development of Effective Immunotherapy for Prostate Cancer Patients: Phase I/II Study of Human GM-CSF Gene-Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX�) in Advanced Prostate Cancer Patients Made Lymphopenic by Chemotherapy and Infused with Autologous Peripheral Blood Mononuclear Cells
|
|
|
| |
|
677: Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV-RPE65) Gene Vector in Patients with Retinal Disease Due to RPE65 Mutations
|
|
|
| |
|
679: Phase I Clinical Trial of rAAV2.5-CMV-Minidystrophin Gene Vector in Duchenne Muscular Dystrophy
|
|
|
| |
|
681: Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer after Nonmyeloablative Conditioning
|
|
|
| |
|
689: A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects with Ideopathic Parkinson�s Disease
|
|
|
| |
|
691: Phase I Trial of Systemic Administration of Edmonston Strain of Measle Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma
|
|
|
| |
|
699: A Pilot Study of Temozolomide and O 6-Benzylguanine for Treatment of High-Grade Glioma Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection
|
|
|
| |
|
703: Phase I Safety, Dose-Escalating Study of MultiGeneAngio in Patients with Peripheral Arterial Disease
|
|
|
| |
|
707: Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus against Malignant Glioma
|
|
|
| |
|
725: A Phase I Pilot Study of Safety and Feasibility of Stem Cell Therapy for AIDS Lymphoma Using Stem Cells Treated with a Lentivirus Vector Encoding Multiple Anti-HIV RNAs
|
|
|
| |
|
727: Clinical Translation of a Mammaglobin-A DNA Vaccine for Breast Cancer Prevention and Therapy
|
|
|
| |
|
731: Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adenoviral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals with Irradiation-Induced Parotid Salivary Hypofunction
|
|
|
| |
|
732: A Phase I/IIA Dose-Escalation Trial of Intratumoral Injection with Oncolytic Adenovirus Vector INGN 007 (VRX-007) in Patients with Advanced Solid Tumors
|
|
|
| |
|
734: An Open-Label, Phase I, Dose-Escalation Study of AD-EGFR-CD533 and Surgery for Patients with Resectable Recurrent High-Grade Glioma
|
|
|
| |
|
739: Transduction of the Upper Airway Epithelium in Humans with Cystic Fibrosis by an AAV6 Vector That Encodes Human Placental Alkaline Phosphatase
|
|
|
| |
|
740: A Phase I Safety Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 into the Retinal Pigment Epithelium (RPE)
|
|
Top of Page |
